ASML vs BLSH

ASML exhibits strong financial health with a Piotroski F-Score of 4/9, indicating stable fundamentals despite not reaching the 'strong' threshold. The company's robust profitability metrics—especially a 50.46% ROE and 29.42% profit margin—underscore its operational excellence. While the current price of $1,345.69 trades at a premium to both the Graham Number ($193.99) and Intrinsic Value ($507.83), this is justified by exceptional growth prospects and dominant market positioning in semiconductor equipment. The recent earnings beat rate of 50% over the last four quarters and consistent positive surprises support a bullish outlook. The absence of an Altman Z-Score does not indicate distress risk, as the company maintains a low debt-to-equity ratio (0.24) and strong liquidity. Price trades at a 28.2% premium to fair value estimate ($1050.00), limiting near-term upside from a valuation perspective.

The company exhibits severe financial health concerns with a Piotroski F-Score of just 2/9, indicating weak fundamental strength. Despite impressive revenue growth (98% YoY) and strong operating metrics like 100% gross margin and 56.8% operating margin, profitability remains negative (net margin: -30.71%) and key valuation multiples are stretched, with a forward P/E of 51.31 and Price/Sales of 27.10. The stock has declined 47.4% over 1Y, 3Y, and 5Y periods, reflecting persistent investor skepticism, while analyst target of $51.00 suggests optimism but lacks consensus depth. Missing earnings estimates in all three reported quarters and lack of Altman Z-Score due to incomplete data further undermine confidence.